Clinical tests at the Oklahoma Medical Research Foundation of an experimental drug proved successful in slowing the spread of an enzyme believed to cause Alzheimer's disease.

By Jim Killackey, The Oklahoman Jan. 15--Using humans in clinical trials for the first time, local scientists found that an experimental drug to treat Alzheimer's disease is safe and effective in halting progression of the memory-robbing illness.

CoMentis, Inc., a privately held biopharmaceutical company, announced today that it has completed a Phase I study of its proprietary, orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer's disease.

By Jerry Shottenkirk Jordan Tang at the Oklahoma Medical Research Foundation has been steadily taking steps in his assault on Alzheimer's disease, and he recently took another. Tang is at the forefront of a new study that shows that a shot could help prevent the debilitating disease.

By DAVID HARPER An Oklahoma study involving immunized mice shows promise. The fight against Alzheimer's disease has gotten a shot in the arm.